|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT02355509 |
|
Date of registration:
|
21/01/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients
|
|
Scientific title:
|
Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients |
|
Date of first enrolment:
|
January 2010 |
|
Target sample size:
|
21 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT02355509 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
|
|
Phase:
|
Phase 4
|
|
|
Countries of recruitment
|
|
Mexico
| | | | | | | |
|
Contacts
|
|
Name:
|
Fracisco J Gómez-Pérez, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Recent diagnosis of carbohydrate intolerance according to the WHO criteria, without
any treatment.
Exclusion Criteria:
- patients with BMI >32 kg/m2, triglycerides and/or total cholesterol > 300 mg/dl,
known renal, liver or gastrointestinal disease and positive smoking.
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Glucose Intolerance
|
|
Cardiovascular Risk Factor
|
|
Postprandial Hyperglycemia
|
|
Intervention(s)
|
|
Drug: Acarbose
|
|
Drug: Placebo
|
|
Primary Outcome(s)
|
|
Change in postprandial oxLDL
[Time Frame: 3 months treatment]
|
|
Secondary Outcome(s)
|
|
Change in HDL concentration
[Time Frame: 3 months treatment]
|
|
Change in Apolipoprotein B (ApoB) concentration
[Time Frame: 3 months treatment]
|
|
Change in LDL concentration
[Time Frame: 3 months treatment]
|
|
Chance in postprandial insulin levels
[Time Frame: 3 months treatment]
|
|
Chance in postprandial hyperglycemia
[Time Frame: 3 months treatment]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|